聚酰亚胺树脂基复合摩擦材料成型技术研究进展

简要介绍了聚酰亚胺(PI)复合摩擦材料的发展概况,综述了热模压成型、冷⁃热等静压和3D打印以及其他成型技术如注射成型、挤出成型等方法制备PI复合摩擦材料的研究进展,最后展望了其成型技术的发展前景,旨在为高性能PI树脂基复合摩擦材料的开发提供有益参考。

聚酰亚胺及其复合材料的摩擦学改性研究进展

本文从分子结构的摩擦学改性、表面改性、共混改性和复合改性综述了聚酰亚胺及其复合材料的摩擦学改性研究进展,并简要介绍了我国聚酰亚胺摩擦材料的发展现状,为高性能聚合物基摩擦材料的设计与性能优化提供参考。

基于中医药文化和健康旅游视角提出张仲景文化品牌建设对策

当今,中医药文化和健康旅游走向融合,有着内在的必然依据,它们孕育出的中医药健康旅游新业态给中医药文化发展和旅游业的创新注入了新的活力。作为中医药产业文化代表的张仲景文化,应抓住机遇,借助健康旅游实现张仲景品牌建设的新突破。主要建设策略有:积极推出以张仲景等中华名医事迹为题材的图书或影视剧;将中药材种植基地开辟为特色旅游观光园;创立中医药文化研究及传播基地,建设学、疗、游为一体的中医药疗养旅游基地;利用信息技术和文化媒体平台将张仲景中医药学绍介到千家万户。

热固性聚酰亚胺复合材料的往复摩擦磨损性能研究

采用热模压成型方法制备了玄武岩纤维增强、多元填料改性的热固性聚酰亚胺复合材料,研究了复合材料的组织结构、摩擦磨损性能与磨损机制。结果表明:所制备的多元复合材料组织致密,玄武岩纤维和各填料分散均匀,硬度明显高于纯聚酰亚胺(PI)和玄武岩纤维改性聚酰亚胺(BF/PI)。摩擦磨损实验结果表明,多元复合材料具有优良的耐磨性能和摩擦稳定性,摩擦系数明显低于PI和BF/PI,磨损率分别较纯PI试样和BF/PI试样低约50.3%和19.9%。

芒柄花黄素改善脂多糖诱导的小鼠抑郁样行为和神经炎症的作用研究

目的:观察芒柄花黃素(formononetin,FMN)对脂多糖(lipopolysaccharide,LPS)诱导的小鼠抑郁样行为和神经炎症的影响。方法:雄性ICR小鼠随机分为正常组、LPS组、帕罗西江组(20 mg·kg^(-1))、FMN低剂量组(20 mg·kg^(-1)),FMN高剂量组(40 mg·kg^(-1)),每组8只,灌胃给药14天后采用糖水偏好实验(sucrose preference test,SPT)、悬尾实验(tail suspension test,TST)和旷场实验(open field test,OFT)观察小鼠抑郁样行为;采用晦联免疫吸附测定实验(enzyme-linked immunosorbent assay,ELISA)和实时荧光定量聚合晦链式反应实验(real-time quantitative polymerase chain reaction,qRT-PCR)测定小鼠海马组织中白细胞介素-6(interleukin-6,IL-6)、IL-1β和肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)的蛋白和mRNA表达水平;采用免疫荧光染色观察小鼠海马组织中小胶质细胞钙结合蛋白-1(ionized calcium binding adapter molecule1,Iba-1)的表达水平以评价小胶质细胞活化水平。结果:与正常组相比,LPS组小鼠糖水偏好率、中心区域活动时间、中心区域活动距离、进入中心区域的次数显著下降(P<0.01),TST不动时间显著延长(P<0.05),海马组织IL-6、IL-1β和TNF-α蛋白及mRNA表达水平显著升高(P<0.01),海马组织CA1、CA3和DG区域Iba-1荧光强度显著增加(P<0.01)。与LPS组相比,FMN组小鼠糖水偏好率、中心区域活动时间、中心区域活动距离和进入中心区域的次数均显著升高(P<0.05或P<0.01),TST不动时间显著缩短(P<0.01),海马组织IL-6、IL-1β和TNF-α蛋白及mRNA表达水平显著降低(P<0.05或P<0.01),海马组织CA1、CA3和DG区域Iba-1荧光强度显著降低(P<0.01)。结论:FMN可能通过抑制LPS诱导的小胶质细胞活化,减轻海马神经炎症,改善小鼠的抑郁样行为。

玄武岩纤维含量对聚酰亚胺树脂基复合材料摩擦磨损性能的影响

采用热模压工艺制备了不同玄武岩纤维含量的聚酰亚胺树脂基复合材料,研究了纤维含量对复合材料硬度、弯曲强度和摩擦磨损性能的影响。结果表明,KH550改性玄武岩纤维(KBF)能够显著提高聚酰亚胺树脂(PI)的摩擦磨损性能。KBF含量在5%~15%(质量分数)增加时,KBF/PI复合材料的硬度和弯曲强度均明显增加,磨损率则明显降低;其中,KBF质量分数为10%和15%时,试样的弯曲强度较PI试样分别高约71.4%和214.3%,磨损率分别低约50%和60%。

A review of research on the chemical constituents and pharmacological effects of Elephantopus tomentosus L.

Elephantopus tomentosus,belonging to the genus Elephantopus,is widely distributed in the coastal areas of southern China and tropical regions,used locally as traditional folk medicine.Previous phytochemistry studies on Elephantopus tomentosus led to the isolation of sesquiterpenoids,triterpenoids,flavonoids and other compounds.Research has shown that these compounds possess multiple biological activities,which have attracted great attention of researchers worldwide.This study reviews the chemical constituents and biological activities of the Elephantopus tomentosus in order to better explore and utilize Elephantopus tomentosus.

加味丹栀逍遥散肝脑同治抑郁症的研究进展

中医基于整体观念、辨证论治防治抑郁症具有独特优势。肝郁脾虚证是抑郁症的主要证型,而丹栀逍遥散具有疏肝解郁、养血健脾之功效,针对肝郁脾虚这一证型,且现有研究已证实其抗抑郁功效。药效物质基础研究发现,丹栀逍遥散治疗抑郁症的主要活性成分包括柴胡皂苷、丹皮酚、栀子苷、当归多糖、硫酸茯苓多糖、芍药苷、芍药内酯苷、苍术酮等。临床中,为使丹栀逍遥散更符合病机特点和病情变化,多对其进行加减应用。本课题组在临床实践中发现“脑神失用,肝失疏泄”为抑郁症的主要病机,基于“肝脑同治”理论提出了“疏肝解郁,健脑益智”的治则,并在丹栀逍遥散的基础上加石菖蒲开窍醒神,远志安神益智,合方共成加味丹栀逍遥散,临床治疗抑郁症疗效显著。动物实验亦证实,加味丹栀逍遥散能显著改善抑郁模型大鼠的抑郁样行为,其机制可能与调节下丘脑-垂体-肾上腺轴(the hypothalamic-pituitary-adrenal axis,HPA轴),升高5-羟色胺(5-Hydrotryptamine,5-HT)和去甲肾上腺素(norepinephrine,NE)的含量有关,为进一步推广加味丹栀逍遥散治疗抑郁症的临床应用提供了参考。

TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites:An updated meta-analysis

AIM:To compare the liver transplantation-free(LTF)survival rates between patients who underwent transjugular intrahepatic portosystemic shunts(TIPS)and those who underwent paracentesis by an updated meta-analysis that pools the effects of both number of deaths and time to death.METHODS:MEDLINE,EMBASE,and the Cochrane Library were searched from the inception to October2012.LTF survival,liver transplantation,liver diseaserelated death,non-liver disease-related death,recurrent ascites,hepatic encephalopathy(HE)and severe HE,and hepatorenal syndrome were assessed as outcomes.LTF survival was estimated using a HR with a95%CI.Other outcomes were estimated using OR with95%CIs.Sensitivity analyses were performed to assess the effects of potential outliers in the studies according to the risk of bias and the study characteristics.RESULTS:Six randomized controlled trials with 390patients were included.In comparison to paracentesis,TIPS significantly improved LTF survival(HR=0.61,95%CI:0.46-0.82,P<0.001).TIPS also significantly decreased liver disease-related death(OR=0.62,95%CI:0.39-0.98,P=0.04),recurrent ascites(OR=0.15,95%CI:0.09-0.24,P<0.001)and hepatorenal syndrome(OR=0.32,95%CI:0.12-0.86,P=0.02).However,TIPS increased the risk of HE(OR=2.95,95%CI:1.87-4.66,P=0.02)and severe HE(OR=2.18,95%CI:1.27-3.76,P=0.005).CONCLUSION:TIPS significantly improved the LTF survival of cirrhotic patients with refractory ascites and decreased the risk of recurrent ascites and hepatorenal syndrome with the cost of increased risk of HE compared with paracentesis.Further studies are warranted to validate the survival benefit of TIPS in clinical practice settings.

Shunting branch of portal vein and stent position predict survival after transjugular intrahepatic portosystemic shunt

AIM:To evaluate the effect of the shunting branch of the portal vein(PV)(left or right)and the initial stent position(optimal or suboptimal)of a transjugular intrahepatic portosystemic shunt(TIPS).METHODS:We retrospectively reviewed 307 consecu5tive cirrhotic patients who underwent TIPS placement for variceal bleeding from March 2001 to July 2010 at our center.The left PV was used in 221 patients and the right PV in the remaining 86 patients.And,224 and83 patients have optimal stent position and sub-optimal stent positions,respectively.The patients were followed until October 2011 or their death.Hepatic encephalopathy,shunt dysfunction,and survival were evaluated as outcomes.The difference between the groups was compared by Kaplan-Meier analysis.A Cox regression model was employed to evaluate the predictors.RESULTS:Among the patients who underwent TIPS to the left PV,the risk of hepatic encephalopathy(P=0.002)and mortality were lower(P<0.001)compared to those to the right PV.Patients who underwent TIPS with optimal initial stent position had a higher primary patency(P<0.001)and better survival(P=0.006)than those with suboptimal initial stent position.The shunting branch of the portal vein and the initial stent position were independent predictors of hepatic encephalopathy and shunt dysfunction after TIPS,respectively.And,both were independent predictors of survival.CONCLUSION:TIPS placed to the left portal vein with optimal stent position may reduce the risk of hepatic encephalopathy and improve the primary patency rates,thereby prolonging survival.

Nonselective beta-blockers in cirrhotic patients with no or small varices:A meta-analysis

AIM:To explore effects of nonselective beta-blockers(NSBBs) in cirrhotic patients with no or small varices.METHODS:The Pub Med,EMBASE,Science Direct,and Cochrane library databases were searched for relevant papers.A meta-analysis was performed using ORs with 95%CI as the effect sizes.Subgroup analysis was conducted according to the studies including patients without varices and those with small varices.RESULTS:Overall,784 papers were initially retrieved from the database searches,of which six randomized controlled trials were included in the meta-analysis.The incidences of large varices development(OR = 1.05,95%CI:0.25-4.36;P = 0.95),first upper gastrointestinal bleeding(OR = 0.59,95%CI:0.24-1.47;P = 0.26),and death(OR = 0.70,95%CI:0.45-1.10;P = 0.12) were similar between NSBB and placebo groups.However,the incidence of adverse events was significantly higher in the NSBB group compared with the placebo group(OR = 3.47,95%CI:1.45-8.33;P = 0.005).The results of subgroup analyses were similar to those of overall analyses.CONCLUSION:The results of this meta-analysis indicate that NSBBs should not be recommended for cirrhotic patients with no or small varices.

Selection of a TIPS stent for management of portal hypertension in liver cirrhosis: An evidence-based review

Nowadays,transjugular intrahepatic portosystemic shunt(TIPS)has become a mainstay treatment option for the management of portal hypertension-related complications in liver cirrhosis.Accumulated evidence has shown that its indications are being gradually expanded.Notwithstanding,less attention has been paid for the selection of an appropriate stent during a TIPS procedure.Herein,we attempt to review the current evidence regarding the diameter,type,brand,and position of TIPS stents.Several following recommendations may be considered in the clinical practice:(1)a 10-mm stent may be more effective than an 8-mm stent for the management of portal hypertension,and may be superior to a 12-mm stent for the improvement of survival and shunt patency;(2)covered stents are superior to bare stents for reducing the development of shunt dysfunction;(3)if available,Viatorr stent-grafts may be recommended due to a higher rate of shunt patency;and(4)the placement of a TIPS stent in the left portal vein branch may be more reasonable for decreasingthe development of hepatic encephalopathy.However,given relatively low quality of evidence,prospective well-designed studies should be warranted to further confirm these recommendations.

Persimmon leaf flavonoid promotes brain ischemic tolerance

Persimmon leaf flavonoid has been shown to enhance brain ischemic tolerance in mice, but its mechanism of action remains unclear. The bilateral common carotid arteries were occluded using a micro clip to block blood flow for 10 minutes. After 10 minutes of ischemic preconditioning, 200,100, and 50 mg/kg persimmon leaf flavonoid or 20 mg/kg ginaton was intragastrically administered per day for 5 days. At 1 hour after the final administration, ischemia/reperfusion models were estab- lished by blocking the middle cerebral artery for 2 hours. At 24 hours after model establishment, compared with cerebral ischemic rats without ischemic preconditioning or drug intervention, plasma endothelin, thrombomodulin and yon Willebrand factor levels significantly decreased and intercel- lular adhesion molecule-1 expression markedly reduced in brain tissue from rats with ischemic pre- conditioning. Simultaneously, brain tissue injury reduced. Ischemic preconditioning combined with drug exposure noticeably improved the effects of the above-mentioned indices, and the effects of 200 mg/kg persimmon leaf flavonoid were similar to 20 mg/kg ginaton treatment. These results indicate that ischemic preconditioning produces tolerance to recurrent severe cerebral ischemia. However, persimmon leaf flavonoid can elevate ischemic tolerance by reducing inflammatory reactions and vascular endothelial injury. High-dose persimmon leaf flavonoid showed an identical effect to ginaton.

Nonselective β-blockers may induce development of portal vein thrombosis in cirrhosis

Currently, nonselective β-blockers(NSBBs) are commonly used for the prevention of variceal bleeding in liver cirrhosis. The beneficial effects of NSBBs are primarily attributed to the reduction in cardiac output by blockade of β1 receptors and vasoconstriction of the splanchnic circulation by the blockade of β2 receptors. The prognostic value of occlusive portal vein thrombosis(PVT) in cirrhotic patients has been increasingly recognized. The most important risk factor for the development of PVT in liver cirrhosis is the decreased portal vein inflow velocity. Collectively, we propose that the use of NSBBs potentially increases the development of portal vein thrombosis by reducing portal vein inflow velocity. The hypothesis should be confirmed by prospective cohort studies, in which cirrhotic patients without prior PVT treated with and without NSBBs are enrolled, and the development of PVT during followup is compared between the two groups. Additionally,subgroup analyses should be performed according to the dosage of NSBBs and the reduction of portal inflow velocity after use of NSBBs.

Restrictive vs liberal transfusion for upper gastrointestinal bleeding:A meta-analysis of randomized controlled trials

AIM:To compare the outcome of upper gastrointestinal bleeding(UGIB) between patients receiving restrictive and liberal transfusion.METHODS:PubMed,EMBASE,and Cochrane Library databases were employed to identify all relevant randomized controlled trials regarding the outcome of UGIB after restrictive or liberal transfusion. Primary outcomes were death and rebleeding. Secondary outcomes were length of hospitalization,amount of blood transfused,and hematocrit and hemoglobin at discharge or after expansion.RESULTS:Overall,4 papers were included in this meta-analysis. The incidence of death was significantly lower in patients receiving restrictive transfusion than those receiving liberal transfusion(OR:0.52,95%CI:0.31-0.87,P = 0.01). The incidence of rebleeding was lower in patients receiving restrictive transfusion than those receiving liberal transfusion,but this difference did not reach any statistical significance(OR:0.26,95%CI:0.03-2.10,P = 0.21). Compared with those receiving liberal transfusion,patients receiving restrictive transfusion had a significantly shorter length of hospitalization(standard mean difference:-0.17,95%CI:-0.30--0.04,P = 0.009) and a significantly smaller amount of blood transfused(standard mean difference:-0.74,95%CI:-1.15--0.32,P = 0.0005) with a lower hematocrit and hemoglobin level at discharge or after expansion.CONCLUSION:Restrictive transfusion should be employed in patients with UGIB.

Prognostic factors in non-malignant and non-cirrhotic patients with portal cavernoma: An 8-year retrospective single-center study

AIM:To evaluate the outcome of non-malignant and non-cirrhotic patients with portal cavernoma and to determine the predictors for survival.METHODS:Between July 2002 and June 2010,we retrospectively enrolled all consecutive patients admitted to our department with a diagnosis of portal cavernoma without abdominal malignancy or liver cirrhosis.The primary endpoint of this observational study was death and cause of death.Independent predictors of survival were identified using the Cox regression model.RESULTS:A total of 64 patients were enrolled in the study.During a mean follow-up period of 18±2.41mo,7 patients died.Causes of death were pulmonary embolism(n=1),acute leukemia(n=1),massive esophageal variceal hemorrhage(n=1),progressive liver failure(n=2),severe systemic infection secondary to multiple liver abscesses(n=1)and accident(n=1).The cumulative 6-,12-and 36-mo survival rates were 94.9%,86%and 86%,respectively.Multivariate Cox regression analysis demonstrated that the presence of ascites(HR=10.729,95%CI:1.209-95.183,P=0.033)and elevated white blood cell count(HR=1.072,95%CI:1.014-1.133,P=0.015)were independent prognostic factors of non-malignant and non-cirrhotic patients with portal cavernoma.The cumulative 6-,12-and 36-mo survival rates were significantly different between patients with and without ascites(90%,61.5%and 61.5%vs 97.3%,97.3%and 97.3%,respectively,P=0.0008).CONCLUSION:The presence of ascites and elevated white blood cell count were significantly associated with poor prognosis in non-malignant and non-cirrhotic patients with portal cavernoma.

EVS vs TIPS shunt for gastric variceal bleeding in patients with cirrhosis:A meta-analysis

AIM: To evaluate the clinical effects of transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic variceal sclerotherapy (EVS) in the management of gastric variceal (GV) bleeding in terms of variceal rebleeding, hepatic encephalopathy (HE), and survival by meta-analysis.METHODS: Medline, Embase, and CNKI were searched. Studies compared TIPS with EVS in treating GV bleeding were identified and included according to our predefined inclusion criteria. Data were extracted independently by two of our authors. Studies with prospective randomized design were considered to be of high quality. Hazard ratios (HRs) or odd ratios(ORs) were calculated using a fixed-effects model when there was no inter-trial heterogeneity. Oppositely, a random-effects model was employed.RESULTS: Three studies with 220 patients who had at least one episode of GV bleeding were included in the present meta-analysis. The proportions of patients with viral cirrhosis and alcoholic cirrhosis were 39% (range 0%-78%) and 36% (range 12% to 41%), respectively. The pooled incidence of variceal rebleeding in the TIPS group was significantly lower than that in the EVS group (HR = 0.3, 0.35, 95% CI: 0.17-0.71, P = 0.004). However, the risk of the development of any degree of HE was significantly increased in the TIPS group (OR = 15.97, 95% CI: 3.61-70.68). The pooled HR of survival was 1.26(95% CI: 0.76-2.09, P = 0.36). No inter-trial heterogeneity was observed among these analyses. CONCLUSION: The improved effect of TIPS in the prevention of GV rebleeding is associated with an increased risk of HE. There is no survival difference between the TIPS and EVS groups. Further studies are needed to evaluate the survival benefit of TIPS in cirrhotic patients with GV bleeding.

Exosomal miR-155 from gastric cancer induces cancerassociated cachexia by suppressing adipogenesis and promoting brown adipose differentiation via C/EPBβ

Objective:The aim of this research was to identify whether exosomes were involved in impairing adipogenesis in cancer-associated cachexia(CAC)by detecting the adipodifferentiation capacity and the expressions of adipogenic proteins in gastric cancer(GC)-associated adipocytes.Methods:Western blotting and RT-PCR were used to investigate the expressions of C/EPBβ,C/EPBα,PPARγ,and UCP1 in adipose mesenchymal stem cells(A-MSCs)to evaluate the function of exosomal miR-155.BALB/c nude mice were intravenously injected in vivo with GC exosomes with different levels of miR-155 to determine changes in adipodifferentiation of A-MSCs.Results:Exosomes derived from GC cells suppressed adipogenesis in A-MSCs as characterized by decreased lipid droplets.Similarly,A-MSCs co-cultured with GC exosomes exhibited increased ATP production through brown adipose differentiation characterized by highly dense mitochondria and enhanced UCP1 expression(P<0.05).Mechanistically,exosomal miR-155 secreted from GC cells suppressed adipogenesis and promoted brown adipose differentiation by targeting C/EPBβ,accompanied by downregulated C/EPBαand PPARγand upregulated UCP1(P<0.05).Moreover,overexpression of miR-155 in GC exosomes improved CAC in vivo,which was characterized by fat loss,suppressed expressions of C/EPBβ,C/EPBα,and PPARγin A-MSCs,and high expression of UCP1(P<0.05).Decreasing the level of miR-155 in injected GC exosomes abrogated the improved CAC effects.Conclusions:GC exosomal miR-155 suppressed adipogenesis and enhanced brown adipose differentiation in A-MSCs by targeting C/EPBβof A-MSCs,which played a crucial role in CAC.

Combined thrombectomy and intracoronary administration of glycoprotein IIb/IIIa inhibitors improves myocardial reperfusion in patients undergoing primary percutaneous coronary intervention： a meta-analysis

BackgroundSuboptimal 心肌的灌注在有圣片断举起的病人是普通的经历主要经皮的冠的干预(PPCI ) 的心肌的梗塞(STEMI ) 。而且，它导致增加的梗塞尺寸和死亡率。我们执行了元分析评估渴望 thrombectomy 的角色(在)在心肌的灌注和临床的 outcomes.MethodsPubMed 的改进与 glycoprotein IIb/IIIa 禁止者( GPI )的 intracoronary 管理结合了， Embase ，科学的网，并且中央数据库被寻找因为调查的使随机化的控制试用( RCT )联合了在并且 intracoronary GPI 治疗对在独自一个。利息的结果是在心肌的梗塞的 thrombolysis 心肌的灌注等级( TMPG )，梗塞尺寸()由心脏的磁性的回声成像估计了，左室的喷射部分( LVEF )，主要不利心脏的事件(向)在短期( 1 个月)并且长期( 6-12 月)后续，并且在包含 923 个病人的医院 stay.ResultsEight 试用期间为复杂并发症放血被包括。与相比在独自一个，联合了在， intracoronary GPI 显著地增加了 TMPG 3 流动(RR：1.15， 95% CI：1.04 ～ 1.26 ) ，减少[吝啬的差别(MD ) ：-3.46,95% CI：-5.18 到 -1.73], 和改进 LVEF (MD：1.44， 95% CI：0.54 ～ 2.33 ) 。而且， GPI 使用减少了在长期的后续的向的风险(RR：0.60， 95% CI：0.37 ～ 0.98 ) 。在未成年者的发生的二个组之间没有重要差别，主要流血 complications.ConclusionsOur 调查结果显示出那与相比在独自一个，联合了在， intracoronary GPI 治疗导致了改进心肌的灌注，更好心脏的功能，并且没有向的幸存与经历 PPCI 的 STEMI 为病人在长期的后续受益。

Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma

Objective:The mainstay treatment of esophageal squamous cell carcinoma(ESCC)involves chemotherapy and immunotherapy.However,alternative therapies are required for patients who are refractory or intolerant to existing therapies.Methods:In this single-arm,multicenter,open-label phase Ib study,30 patients received an intravenous infusion of SCT200,an antiepidermal growth factor receptor(EGFR)monoclonal antibody,6.0 mg/kg once a week for 6 weeks,followed by 8.0 mg/kg once every 2 weeks until disease progression or intolerable toxicity.The primary endpoint was the objective response rate(ORR).The secondary endpoints were progression-free survival(PFS),overall survival(OS),and safety.Results:Thirty patients were enrolled between July 2018 and May 2019.The ORR was 16.7%(95%CI:5.6%–34.7%).The median PFS and OS were 3.1 months(95%CI:1.5–4.3)and 6.8 months(95%CI:4.7–10.1),respectively.A numerical difference without any statistical significance in ORR was observed in patients with different EGFR expressions(≥50%:25.0%vs.<50%:0%,P=0.140)or TP53 mutation abundance(<10%:23.8%vs.≥10%:0%,P=0.286).Improved median PFS(3.4 vs.1.4 months,P=0.006)and OS(8.0 vs.4.2 months,P=0.027)were associated with TP53 mutation abundance of<10%.The most common treatment-related adverse events of grade 3 or 4(occurring in≥2 patients)were hypomagnesemia[7(23.3%)]and rash[2(6.7%)].No treatmentrelated death occurred.Conclusions:SCT200 monotherapy as the second-or further-line treatment for advanced ESCC showed favorable efficacy,with an acceptable safety profile.TP53 mutation abundance might serve as a potential predictive biomarker.